{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:20:19Z","timestamp":1788394819175,"version":"build-2803163510"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76239-3","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:14:01Z","timestamp":1785939241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between na\u00efve B cells and T cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Chaoye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Chen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-589X","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-7730","authenticated-orcid":false,"given":"Masami","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-6205","authenticated-orcid":false,"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Long","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7105-3052","authenticated-orcid":false,"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-6145","authenticated-orcid":false,"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-6235","authenticated-orcid":false,"given":"Miao-Zhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"76239_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"76239_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cac2.70017","volume":"45","author":"M Li","year":"2025","unstructured":"Li, M., Cao, S. & Xu, R. H. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer. Commun. 45, 774\u2013788 (2025).","journal-title":"Cancer. Commun."},{"key":"76239_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/jnci\/djae147","volume":"116","author":"MB Mirza","year":"2024","unstructured":"Mirza, M. B. et al. ERBB2 amplification in gastric cancer: a genomic insight into ethnic disparities. J. Natl. Cancer Inst. 116, 1830\u20131833 (2024).","journal-title":"J. Natl. Cancer Inst."},{"key":"76239_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem, E. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476\u2013484 (2015).","journal-title":"Gastric Cancer"},{"key":"76239_CR5","doi-asserted-by":"crossref","unstructured":"Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169-175 (2017).","DOI":"10.1038\/nature20805"},{"key":"76239_CR6","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","volume":"24","author":"WQ Sheng","year":"2013","unstructured":"Sheng, W. Q. et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann. Oncol. 24, 2360\u20132364 (2013).","journal-title":"Ann. Oncol."},{"key":"76239_CR7","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1002\/ijc.28559","volume":"134","author":"MZ Qiu","year":"2014","unstructured":"Qiu, M. Z. et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J. Cancer 134, 2468\u20132477 (2014).","journal-title":"Int J. Cancer"},{"key":"76239_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-823","volume":"14","author":"M Qiu","year":"2014","unstructured":"Qiu, M. et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer 14, 823 (2014).","journal-title":"BMC Cancer"},{"key":"76239_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang, F. H. et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 44, 127\u2013172 (2024).","journal-title":"Cancer Commun."},{"key":"76239_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"76239_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s44178-022-00004-x","volume":"1","author":"Society of Gastric Cancer of China Anti-Cancer, A.","year":"2022","unstructured":"Society of Gastric Cancer of China Anti-Cancer, A. CACA guidelines for holistic integrative management of gastric cancer. Holist. Integr. Oncol. 1, 3 (2022).","journal-title":"Holist. Integr. Oncol."},{"key":"76239_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197\u20132208 (2023).","journal-title":"Lancet"},{"key":"76239_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"76239_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s44466-026-00025-5","volume":"2","author":"Z-X Wang","year":"2026","unstructured":"Wang, Z.-X. et al. Optimizing immunotherapy for gastrointestinal tract cancers: clinical progress and perspectives. Immun. Inflamm. 2, 10 (2026).","journal-title":"Immun. Inflamm."},{"key":"76239_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"76239_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"76239_CR17","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. Jama 330, 2064\u20132074 (2023).","journal-title":"Jama"},{"key":"76239_CR18","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. Bmj 385, e078876 (2024).","journal-title":"Bmj"},{"key":"76239_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313\u2013326 (2018).","journal-title":"Cell"},{"key":"76239_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"key":"76239_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59622-4","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity. Nat. Commun. 16, 4454 (2025).","journal-title":"Nat. Commun."},{"key":"76239_CR22","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.ccell.2024.09.011","volume":"42","author":"E Fitzsimons","year":"2024","unstructured":"Fitzsimons, E. et al. A pan-cancer single-cell RNA-seq atlas of intratumoral B cells. Cancer Cell 42, 1784\u20131797.e1784 (2024).","journal-title":"Cancer Cell"},{"key":"76239_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumor immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76239_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaoncol.2022.6288","volume":"9","author":"A Fernandez-Martinez","year":"2023","unstructured":"Fernandez-Martinez, A. et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2\/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 9, 490\u2013499 (2023).","journal-title":"JAMA Oncol."},{"key":"76239_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41416-024-02835-z","volume":"131","author":"C Chen","year":"2024","unstructured":"Chen, C. et al. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer. Br. J. Cancer 131, 1463\u20131472 (2024).","journal-title":"Br. J. Cancer"},{"key":"76239_CR26","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1200\/JCO.2024.42.16_suppl.606","volume":"42","author":"P-H Lin","year":"2024","unstructured":"Lin, P.-H., Lo, C., Kuo, S.-H. & Huang, C.-S. The predictive value of the mature B cell signature in early Her2-positive breast cancer treated with neoadjuvant therapy. J. Clin. Oncol. 42, 606\u2013606 (2024).","journal-title":"J. Clin. Oncol."},{"key":"76239_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-21-0888","volume":"12","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer. Cancer Discov. 12, 984\u20131001 (2022).","journal-title":"Cancer Discov."},{"key":"76239_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02085-w","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer. Mol. Cancer 23, 169 (2024).","journal-title":"Mol. Cancer"},{"key":"76239_CR29","doi-asserted-by":"publisher","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","volume":"35","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma. Ann. Oncol. 35, S877\u2013S878 (2024).","journal-title":"Ann. Oncol."},{"key":"76239_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41392-023-01622-1","volume":"8","author":"MZ Qiu","year":"2023","unstructured":"Qiu, M. Z. et al. Dynamic single-cell mapping unveils Epstein\u2012Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduct. Target Ther. 8, 370 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"76239_CR31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim, S. T. et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med 24, 1449\u20131458 (2018).","journal-title":"Nat. Med"},{"key":"76239_CR32","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929\u2013938 (2022).","journal-title":"Ann. Oncol."},{"key":"76239_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41588-023-01333-x","volume":"55","author":"Y Totoki","year":"2023","unstructured":"Totoki, Y. et al. Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat. Genet 55, 581\u2013594 (2023).","journal-title":"Nat. Genet"},{"key":"76239_CR34","doi-asserted-by":"publisher","first-page":"e010024","DOI":"10.1136\/jitc-2024-010024","volume":"13","author":"J Veas Rodriguez","year":"2025","unstructured":"Veas Rodriguez, J. et al. Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. J. Immunother. Cancer 13, e010024 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"76239_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","volume":"31","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat. Med. 31, 1519\u20131530 (2025).","journal-title":"Nat. Med."},{"key":"76239_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123\u20131136 (2022).","journal-title":"Nat. Cancer"},{"key":"76239_CR37","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918\u20132935.e2929 (2022).","journal-title":"Cell"},{"key":"76239_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo, X. et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell 43, 248\u2013268.e249 (2025).","journal-title":"Cancer Cell"},{"key":"76239_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi9591","volume":"376","author":"J Li","year":"2022","unstructured":"Li, J. et al. KIR(+)CD8(+) T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Science 376, eabi9591 (2022).","journal-title":"Science"},{"key":"76239_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41590-024-02023-4","volume":"26","author":"BY Lu","year":"2025","unstructured":"Lu, B. Y. et al. Circulating tumor-reactive KIR(+)CD8(+) T cells suppress anti-tumor immunity in patients with melanoma. Nat. Immunol. 26, 82\u201391 (2025).","journal-title":"Nat. Immunol."},{"key":"76239_CR41","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593.e1578 (2021).","journal-title":"Cancer Cell"},{"key":"76239_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2159-8290.CD-23-0857","volume":"14","author":"M An","year":"2024","unstructured":"An, M. et al. Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer. Cancer Discov. 14, 766\u2013785 (2024).","journal-title":"Cancer Discov."},{"key":"76239_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s43018-024-00807-z","volume":"5","author":"X Chu","year":"2024","unstructured":"Chu, X. et al. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat. Cancer 5, 1409\u20131426 (2024).","journal-title":"Nat. Cancer"},{"key":"76239_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griss","year":"2019","unstructured":"Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).","journal-title":"Nat. Commun."},{"key":"76239_CR45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.it.2022.01.003","volume":"43","author":"D Morgan","year":"2022","unstructured":"Morgan, D. & Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 43, 210\u2013229 (2022).","journal-title":"Trends Immunol."},{"key":"76239_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/383263a0","volume":"383","author":"M Ono","year":"1996","unstructured":"Ono, M., Bolland, S., Tempst, P. & Ravetch, J. V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383, 263\u2013266 (1996).","journal-title":"Nature"},{"key":"76239_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0092-8674(00)80337-2","volume":"90","author":"M Ono","year":"1997","unstructured":"Ono, M. et al. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 90, 293\u2013301 (1997).","journal-title":"Cell"},{"key":"76239_CR48","doi-asserted-by":"publisher","first-page":"13489","DOI":"10.1073\/pnas.1935944100","volume":"100","author":"GR Ehrhardt","year":"2003","unstructured":"Ehrhardt, G. R. et al. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc. Natl. Acad. Sci. USA 100, 13489\u201313494 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76239_CR49","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1182\/blood-2011-05-353102","volume":"118","author":"HW Sohn","year":"2011","unstructured":"Sohn, H. W., Krueger, P. D., Davis, R. S. & Pierce, S. K. FcRL4 acts as an adaptive to innate molecular switch, dampening BCR signaling and enhancing TLR signaling. Blood 118, 6332\u20136341 (2011).","journal-title":"Blood"},{"key":"76239_CR50","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.immuni.2021.08.005","volume":"54","author":"DC Nascimento","year":"2021","unstructured":"Nascimento, D. C. et al. Sepsis expands a CD39(+) plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. Immunity 54, 2024\u20132041.e2028 (2021).","journal-title":"Immunity"},{"key":"76239_CR51","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1093\/jimmun\/vkaf187","volume":"214","author":"K Jin","year":"2025","unstructured":"Jin, K. et al. Harnessing CD39 inhibition to boost antitumor immunity with extracellular ATP. J. Immunol. 214, 2906\u20132918 (2025).","journal-title":"J. Immunol."},{"key":"76239_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03323-8","volume":"9","author":"M Vigolo","year":"2018","unstructured":"Vigolo, M. et al. A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nat. Commun. 9, 1199 (2018).","journal-title":"Nat. Commun."},{"key":"76239_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-021-00725-x","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang, M. et al. AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1-Bcl-6 axis-mediated B-cell differentiation. Signal Transduct. Target Ther. 6, 341 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"76239_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj4857","volume":"384","author":"J Ma","year":"2024","unstructured":"Ma, J. et al. A blueprint for tumor-infiltrating B cells across human cancers. Science 384, eadj4857 (2024).","journal-title":"Science"},{"key":"76239_CR55","doi-asserted-by":"publisher","first-page":"eabb6296","DOI":"10.1126\/sciadv.abb6296","volume":"6","author":"QH Zeng","year":"2020","unstructured":"Zeng, Q. H. et al. B cells polarize pathogenic inflammatory T helper subsets through ICOSL-dependent glycolysis. Sci. Adv. 6, eabb6296 (2020).","journal-title":"Sci. Adv."},{"key":"76239_CR56","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184, 6101\u20136118.e6113 (2021).","journal-title":"Cell"},{"key":"76239_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/apm.13277","volume":"131","author":"N Kemi","year":"2023","unstructured":"Kemi, N. et al. Tertiary lymphoid structures and gastric cancer prognosis. Apmis 131, 19\u201325 (2023).","journal-title":"Apmis"},{"key":"76239_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03889-3","volume":"23","author":"Y Xie","year":"2025","unstructured":"Xie, Y. et al. Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer. BMC Med. 23, 59 (2025).","journal-title":"BMC Med."},{"key":"76239_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78560-3","volume":"10","author":"Z Lin","year":"2020","unstructured":"Lin, Z. et al. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Sci. Rep. 10, 21530 (2020).","journal-title":"Sci. Rep."},{"key":"76239_CR60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"76239_CR61","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"76239_CR62","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1084\/jem.20091299","volume":"207","author":"C Duy","year":"2010","unstructured":"Duy, C. et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209\u20131221 (2010).","journal-title":"J. Exp. Med."},{"key":"76239_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.V86.1.45.bloodjournal86145","volume":"86","author":"G Cattoretti","year":"1995","unstructured":"Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45\u201353 (1995).","journal-title":"Blood"},{"key":"76239_CR64","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1084\/jem.185.3.563","volume":"185","author":"S Lebecque","year":"1997","unstructured":"Lebecque, S., de Bouteiller, O., Arpin, C., Banchereau, J. & Liu, Y. J. Germinal center founder cells display propensity for apoptosis before onset of somatic mutation. J. Exp. Med. 185, 563\u2013571 (1997).","journal-title":"J. Exp. Med."},{"key":"76239_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","volume":"604","author":"W Kim","year":"2022","unstructured":"Kim, W. et al. Germinal center-driven maturation of B cell response to mRNA vaccination. Nature 604, 141\u2013145 (2022).","journal-title":"Nature"},{"key":"76239_CR66","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","volume":"120","author":"GD Victora","year":"2012","unstructured":"Victora, G. D. et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120, 2240\u20132248 (2012).","journal-title":"Blood"},{"key":"76239_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nri3804","volume":"15","author":"NS De Silva","year":"2015","unstructured":"De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centers. Nat. Rev. Immunol. 15, 137\u2013148 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"76239_CR68","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41590-023-01540-y","volume":"24","author":"R Sharma","year":"2023","unstructured":"Sharma, R. et al. Distinct metabolic requirements regulate B cell activation and germinal center responses. Nat. Immunol. 24, 1358\u20131369 (2023).","journal-title":"Nat. Immunol."},{"key":"76239_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.cell.2019.07.047","volume":"178","author":"M Nagai","year":"2019","unstructured":"Nagai, M. et al. Fasting-Refeeding Impacts Immune Cell Dynamics and Mucosal Immune Responses. Cell 178, 1072\u20131087.e1014 (2019).","journal-title":"Cell"},{"key":"76239_CR70","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cell.2010.10.032","volume":"143","author":"GD Victora","year":"2010","unstructured":"Victora, G. D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592\u2013605 (2010).","journal-title":"Cell"},{"key":"76239_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","volume":"34","author":"CG Vinuesa","year":"2016","unstructured":"Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular Helper T Cells. Annu Rev. Immunol. 34, 335\u2013368 (2016).","journal-title":"Annu Rev. Immunol."},{"key":"76239_CR72","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13569","volume":"109","author":"M Yamamoto","year":"2018","unstructured":"Yamamoto, M. et al. Established gastric cancer cell lines transplantable into C57BL\/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 109, 1480\u20131492 (2018).","journal-title":"Cancer Sci."},{"key":"76239_CR73","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/1097-0142(197512)36:6<2441::AID-CNCR2820360627>3.0.CO;2-P","volume":"36","author":"DP Griswold","year":"1975","unstructured":"Griswold, D. P. & Corbett, T. H. A colon tumor model for anticancer agent evaluation. Cancer 36, 2441\u20132444 (1975).","journal-title":"Cancer"},{"key":"76239_CR74","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096.e3019 (2025).","journal-title":"Cell"},{"key":"76239_CR75","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","volume":"21","author":"S Wu","year":"2019","unstructured":"Wu, S. et al. HER2 recruits AKT1 to disrupt STING signaling and suppress antiviral defense and antitumor immunity. Nat. Cell Biol. 21, 1027\u20131040 (2019).","journal-title":"Nat. Cell Biol."},{"key":"76239_CR76","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29, 1424\u20131436 (2023).","journal-title":"Nat. Med."},{"key":"76239_CR77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.immuni.2022.01.018","volume":"55","author":"R Zander","year":"2022","unstructured":"Zander, R. et al. Tfh-cell-derived interleukin 21 sustains effector CD8(+) T cell responses during chronic viral infection. Immunity 55, 475\u2013493.e475 (2022).","journal-title":"Immunity"},{"key":"76239_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0675","volume":"15","author":"MG Lechner","year":"2023","unstructured":"Lechner, M. G. et al. Clonally expanded, thyrotoxic effector CD8(+) T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci. Transl. Med. 15, eadg0675 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76239_CR79","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.cmet.2021.11.010","volume":"33","author":"P Michael St","year":"2021","unstructured":"Michael St, P. et al. Coenzyme A fuels T cell anti-tumor immunity. Cell Metab. 33, 2415\u20132427.e2416 (2021).","journal-title":"Cell Metab."},{"key":"76239_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado0020","volume":"17","author":"S Sun","year":"2025","unstructured":"Sun, S. et al. Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming. Sci. Transl. Med. 17, eado0020 (2025).","journal-title":"Sci. Transl. Med."},{"key":"76239_CR81","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cmet.2022.02.015","volume":"34","author":"SM Hochrein","year":"2022","unstructured":"Hochrein, S. M. et al. The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming. Cell Metab. 34, 516\u2013532.e511 (2022).","journal-title":"Cell Metab."},{"key":"76239_CR82","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41590-018-0156-5","volume":"19","author":"M Akkaya","year":"2018","unstructured":"Akkaya, M. et al. Second signals rescue B cells from activation-induced mitochondrial dysfunction and death. Nat. Immunol. 19, 871\u2013884 (2018).","journal-title":"Nat. Immunol."},{"key":"76239_CR83","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"ST Crotty","year":"2019","unstructured":"Crotty, S. T. Follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132\u20131148 (2019).","journal-title":"Immunity"},{"key":"76239_CR84","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","volume":"23","author":"RS Herati","year":"2022","unstructured":"Herati, R. S. et al. PD-1-directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat. Immunol. 23, 1183\u20131192 (2022).","journal-title":"Nat. Immunol."},{"key":"76239_CR85","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","volume":"179","author":"DP Hollern","year":"2019","unstructured":"Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191\u20131206.e1121 (2019).","journal-title":"Cell"},{"key":"76239_CR86","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s42255-023-00915-7","volume":"5","author":"P Kreuzaler","year":"2023","unstructured":"Kreuzaler, P. et al. Vitamin B(5) supports MYC oncogenic metabolism and tumor progression in breast cancer. Nat. Metab. 5, 1870\u20131886 (2023).","journal-title":"Nat. Metab."},{"key":"76239_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111741","volume":"41","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Vitamin B5 rewires Th17 cell metabolism via impeding PKM2 nuclear translocation. Cell Rep. 41, 111741 (2022).","journal-title":"Cell Rep."},{"key":"76239_CR88","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41590-025-02153-3","volume":"26","author":"TJ Sanders","year":"2025","unstructured":"Sanders, T. J. et al. Inhibition of ENT1 relieves intracellular adenosine-mediated T-cell suppression in cancer. Nat. Immunol. 26, 854\u2013865 (2025).","journal-title":"Nat. Immunol."},{"key":"76239_CR89","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/1078-0432.CCR-19-1402","volume":"26","author":"C De Angelis","year":"2020","unstructured":"De Angelis, C. et al. Evaluation of the predictive role of tumor immune infiltrate in patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clin. Cancer Res. 26, 738\u2013745 (2020).","journal-title":"Clin. Cancer Res."},{"key":"76239_CR90","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.21.02772","volume":"40","author":"J Huober","year":"2022","unstructured":"Huober, J. et al. Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J. Clin. Oncol. 40, 2946\u20132956 (2022).","journal-title":"J. Clin. Oncol."},{"key":"76239_CR91","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ccell.2024.05.006","volume":"42","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Tumor cells impair immunological synapse formation via a central nervous system-enriched metabolite. Cancer Cell 42, 985\u20131002.e1018 (2024).","journal-title":"Cancer Cell"},{"key":"76239_CR92","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3332\/ecancer.2024.1734","volume":"18","author":"NY Yap","year":"2024","unstructured":"Yap, N. Y., Perumal, K. & Rajadurai, P. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review. Ecancermedicalscience 18, 1734 (2024).","journal-title":"Ecancermedicalscience"},{"key":"76239_CR93","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","volume":"15","author":"B Wilding","year":"2025","unstructured":"Wilding, B. et al. Zongertinib (BI 1810631), an ireversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 15, 119\u2013138 (2025).","journal-title":"Cancer Discov."},{"key":"76239_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1042072","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. Front Immunol. 13, 1042072 (2022).","journal-title":"Front Immunol."},{"key":"76239_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100253","volume":"6","author":"M Kirchner","year":"2021","unstructured":"Kirchner, M. et al. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open 6, 100253 (2021).","journal-title":"ESMO Open"},{"key":"76239_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 14, 550 (2023).","journal-title":"Cell Death Dis."},{"key":"76239_CR97","doi-asserted-by":"publisher","unstructured":"Ramamoorthi, G. et al. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. J Immunother Cancer 10, https:\/\/doi.org\/10.1136\/jitc-2022-004841 (2022).","DOI":"10.1136\/jitc-2022-004841"},{"key":"76239_CR98","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata, T. N. et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 17, 1494\u20131503 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"76239_CR99","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"76239_CR100","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 e324 (2019).","journal-title":"Cell Syst."},{"key":"76239_CR101","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"76239_CR102","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innov. (Camb.) 2, 100141 (2021).","journal-title":"Innov. (Camb.)"},{"key":"76239_CR103","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"76239_CR104","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309\u2013315 (2017).","journal-title":"Nat. Methods"},{"key":"76239_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4772-0","volume":"19","author":"K Street","year":"2018","unstructured":"Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics 19, 477 (2018).","journal-title":"BMC Genomics"},{"key":"76239_CR106","first-page":"377","volume":"24","author":"D Best","year":"1975","unstructured":"Best, D. & Roberts, D. Algorithm AS 89: the upper tail probabilities of Spearman\u2019s rho. J. R. Stat. Soc. Ser. C. (Appl. Stat.) 24, 377\u2013379 (1975).","journal-title":"J. R. Stat. Soc. Ser. C. (Appl. Stat.)"},{"key":"76239_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65421-8","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. Nat. Commun. 16, 10435 (2025).","journal-title":"Nat. Commun."},{"key":"76239_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217412","volume":"611","author":"C Tsutsumi","year":"2024","unstructured":"Tsutsumi, C. et al. TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer. Cancer Lett. 611, 217412 (2024).","journal-title":"Cancer Lett."},{"key":"76239_CR109","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ccell.2026.01.015","volume":"44","author":"Q Zhao","year":"2026","unstructured":"Zhao, Q. et al. Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer. Cancer Cell 44, 809\u2013830.e811 (2026).","journal-title":"Cancer Cell"},{"key":"76239_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33282-0","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nat. Commun. 13, 5723 (2022).","journal-title":"Nat. Commun."},{"key":"76239_CR111","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang, S. et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 53, D1670\u2013d1676 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76239-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:03:02Z","timestamp":1788393782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76239-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76239"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76239-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9424"}}